Summary & Overview
HCPCS J9357: Valrubicin Intravesical Injection, 200 mg
HCPCS Level II code J9357 represents a 200 mg intravesical injection of valrubicin, a locally administered chemotherapeutic agent used in bladder cancer care. This code identifies the drug component of intravesical therapy and matters nationally because it relates to specialty drug utilization, oncology treatment pathways, and outpatient procedure billing across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for intravesical valrubicin, an overview of payer coverage considerations, and typical sites where the service is delivered. The publication summarizes benchmarks and reimbursement patterns, outlines common billing and coding elements associated with intravesical chemotherapy drug codes, and highlights policy updates that affect specialty drug administration in outpatient settings.
The piece is intended for billing managers, oncology and urology practice administrators, and payer policy analysts seeking a clear reference on HCPCS Level II code J9357, how it maps to clinical service, and what to expect in terms of where and why the code is used in routine care.
Billing Code Overview
HCPCS Level II code J9357 describes an intravesical injection of valrubicin, 200 mg. This service represents administration of a chemotherapeutic agent directly into the bladder for local treatment. The service type is intravesical chemotherapy administration, and the typical site of service is an outpatient urology clinic or hospital outpatient department where bladder instillation procedures are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with non‑muscle invasive bladder cancer (NMIBC) who has undergone transurethral resection of bladder tumor (TURBT) and is scheduled for intravesical chemotherapy with valrubicin. The patient presents to the urology clinic or ambulatory infusion suite on the day of treatment. A nurse confirms the treatment order for J9357 (valrubicin, intravesical, 200 mg), verifies allergies and recent urine cytology, and documents baseline vital signs. The urologist or qualified advanced practice provider performs bladder catheterization, instills the 200 mg valrubicin dose in preservative-free diluent, and instructs the patient to retain the instillate for the prescribed dwell time (commonly 1–2 hours) while remaining in the facility or at home per protocol. After dwell time, the nurse facilitates voiding or catheter-assisted drainage and disposes of waste per hazardous drug and biohazard regulations. Clinical documentation includes indication, dose, lot numbers, route intravesical, site of service (typically outpatient hospital department, ambulatory surgical center, or physician office), procedure start and stop times, patient tolerance, and any immediate adverse events. Billing uses HCPCS J9357 for the drug and may require additional CPT codes for catheterization or professional services as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|